| Literature DB >> 30156616 |
Sevgi Akarsu1, Ozlem Ozbagcivan1, Turna Ilknur1, Fatma Semiz1, Burcu Bahar Inci1, Emel Fetil1.
Abstract
BACKGROUND: Current data regarding the associated factors of prurigo nodularis are still uncertain, except for atopic predisposition.Entities:
Mesh:
Year: 2018 PMID: 30156616 PMCID: PMC6106662 DOI: 10.1590/abd1806-4841.20187127
Source DB: PubMed Journal: An Bras Dermatol ISSN: 0365-0596 Impact factor: 1.896
Demographic and clinical characteristics of the women with prurigo nodularis
| Variables | All patients | Xerosis (-) (Group A) | Xerosis (+) (Group B) | Xerosis (+) (Group B) | |||
|---|---|---|---|---|---|---|---|
| Atopic xerosis (Subgroup B1) | Non-atopic xerosis (Subgroup B2) | A vs B | B1 vs B2 | ||||
|
| 80 (100) | 32 (40) | 48 (60) | 16 (20) | 32 (40) | - | - |
|
| |||||||
| Mean±SD (min-max), years | 53.1±17.2 (19-90) | 45.0±12.7 (22-67) | 58.6±17.7 (19-90) | 41.3±13.5 (19-69) | 67.2±12.6 (33-90) | <0.001 | <0.001 |
|
| |||||||
| Mean±SD (min-max), years | 47.9±18.1 (14-88) | 38.5±12.1 (16-59) | 54.1±18.9 (14-88) | 34.6±13.5 (14-67) | 63.8±12.7 (33-88) | <0.001 | <0.001 |
|
| |||||||
| Early adulthood | 41 (51.3) | 23 (71.9) | 18 (37.5) | 14 (87.5) | 4 (12.5) | ||
| Middle adulthood | 22 (27.5) | 9 (28.1) | 13 (27.1) | 1 (6.3) | 12 (37.5) | ||
| Later adulthood | 17 (21.3) | 0 | 17 (35.4) | 1 (6.3) | 16 (50) | ||
|
| |||||||
| Median (interquartile range), months | 48.0 (24 - 84) | 60 (24 - 132) | 42 (24 - 69) | 60 (36 - 93) | 30 (12 -60) | 0.103 | 0.014 |
|
| |||||||
| Localized | 12 (15) | 7(21.9) | 5 (10.4) | 3 (18.8) | 2 (6.3) | 0.206 | 0.316 |
| Generalized | 68 (85) | 25 (78.1) | 43 (89.6) | 13 (81.3) | 30 (93.8) | ||
|
| |||||||
| Lower limbs | 69 (86.3) | 28 (87.5) | 41 (85.4) | 15 (93.8) | 26 (81.3) | 1.00 | 0.398 |
| Trunk | 47 (58.8) | 20 (62.5) | 27 (56.3) | 6 (37.5) | 21 (65.6) | 0.578 | 0.064 |
| Upper limbs | 18 (22.5) | 7(21.9) | 11 (22.9) | 3 (18.8) | 8 (25) | 0.913 | 0.729 |
| Head and neck | 8 (10) | 5 (15.6) | 3 (6.3) | 1 (6.3) | 2 (6.3) | 0.256 | 1.00 |
|
| |||||||
| Median (interquartile range) | 2 (1 - 2) | 2 (1 - 2) | 2 (1 - 2) | 1 (1 - 2) | 2 (1.25 - 2) | 0.436 | 0.135 |
PN, prurigo nodularis; Boldfaced P values indicate statistical significance (P < 0.05).
; Numerical variables without normal distribution were analyzed with Mann-Whitney U test
Number and category of associated factors
| Associated diseases, n (%) | All patients (n=80) | Xerosis (-) (Group A) (n=32) | Xerosis (+) (Group B) (n=48) | Xerosis (+) (Group B) | |||
|---|---|---|---|---|---|---|---|
| Atopic xerosis (Subgroup B1) (n=16) | Non-atopic xerosis (Subgroup B2) (n=32) | A vs B | B1 vs B2 | ||||
|
| |||||||
| Median (interquartile range) | 3 (2 – 4) | 2 (1 - 3) | 4 (2 -5) | 3 (2 -3.8) | 4 (3 -5) | <0.001 | 0.001 |
|
| |||||||
| Undetermined factor | 2 (2.5) | 2 (6.3) | 0 (0) | 0 (0) | 0 (0) | 0.157 | - |
| Single factor | 12 (15) | 8 (25) | 4 (8.3) | 4 (25) | 0 (0) | 0.056 | 0.101 |
| Mixed co-factors | 66 (82.5) | 22 (68.8) | 44 (91.7) | 13 (81.3) | 31 (96.9) | 0.008 | 0.101 |
| Dermatological + systemic* | 20 (25) | 3 (9.4) | 17 (35.4) | 5 (31.3) | 12 (37.5) | ||
| Dermatological + systemic + psychological* | 16 (20) | 3 (9.4) | 13 (27.1) | 3 (18.8) | 10 (31.3) | ||
| Dermatological + psychological* | 6 (7.5) | 4 (12.5) | 2 (4.2) | 2 (12.5) | 0 (0) | ||
| Dermatological + systemic + psychological + neurological* | 6 (7.5) | 1 (3.1) | 5 (1) | 1 (6.3) | 4 (12.5) | ||
| Dermatological + systemic + neurological | 5 (6.3) | 0 (0) | 5 (1) | 0 (0) | 5 (15.6) | ||
| Systemic + psychological | 4 (5) | 4 (12.5) | 0 (0) | 0 (0) | 0 (0) | ||
| Multiple systemic | 2 (2.5) | 2 (6.3) | 0 (0) | 0 (0) | 0 (0) | ||
| Multiple dermatological | 2 (2.5) | 0 (0) | 2 (4.2) | 2 (12.5) | 0 (0) | ||
| Systemic + neurological | 1 (1.3) | 1 (3.1) | 0 (0) | 0 (0) | 0 (0) | ||
| Atopic diathesis + other co-factors** | 4 (5) | 4 (12.5) | 0 (0) | 0 (0) | 0 (0) | ||
Boldfaced P values indicate statistical significance (P < 0.05).
In these groups with mixed co-factors, atopic diathesis was also present in one patient.
Dermatological/systemic/psychological/neurological factors were present in each one patient in addition to atopic diathesis.
; Numerical variables without normal distribution were analyzed with Mann-Whitney U test
Analysis of co-factors in women with prurigo nodularis (total number of co-factors = 45)
| Co-factors, n (%) | All patients (n=80) | Xerosis (-) (Group A) (n=32) | Xerosis (+) (Group B) (n=48) | Xerosis (+) (Group B) | |||
|---|---|---|---|---|---|---|---|
| Atopic xerosis (Subgroup B1) (n=16) | Non-atopic xerosis (Subgroup B2) (n=32) | A vs B | B1 vs B2 | ||||
|
| 63 (78.8) | 15 (46.9) | 48 (100) | 16 (100) | 32 (100) |
|
|
| Xerosis cutis | 48 (60) | 0 (0) | 48 (100) | 16 (100) | 32 (100) | ||
| Atopic diathesis (including atopic dermatitis) | 27 (33.8) | 11 (34.4) | 16 (33.3) | 16 (100) | 0 (0) | ||
| Tinea pedis | 10 (12.5) | 4 (12.5) | 6 (12.5) | 1 (6.3) | 5 (15.6) | ||
| Xerotic eczema | 4 (5) | 0 (0) | 4 (8.3) | 0 (0) | 4 (12.5) | ||
| Urticaria | 4 (5) | 2 (6.3) | 2 (4.2) | 1 (6.3) | 1 (3.1) | ||
| Post-scabies dermatitis | 3 (3.8) | 0 (0) | 3 (6.3) | 0 (0) | 3 (9.4) | ||
| Psoriasis | 2 (2.5) | 1 (3.1) | 1 (2.1) | 1 (6.3) | 0 (0) | ||
| Macular amyloidosis | 2 (2.5) | 1 (3.1) | 1 (2.1) | 1 (6.3) | 0 (0) | ||
| Stasis dermatitis | 2 (2.5) | 1 (3.1) | 1 (2.1) | 0 (0) | 1 (3.1) | ||
| Nummular dermatitis | 2 (2.5) | 1 (3.1) | 1 (2.1) | 1 (6.3) | 0 (0) | ||
| Seborrheic dermatitis | 2 (2.5) | 1 (3.1) | 1 (2.1) | 1 (6.3) | 0 (0) | ||
| Pemphigoid | 2 (2.5) | 1 (3.1) | 1 (2.1) | 0 (0) | 1 (3.1) | ||
| Allergic contact dermatitis | 1 (1.3) | 0 (0) | 1 (2.1) | 1 (6.3) | 0 (0) | ||
| Lichen planus | 1 (1.3) | 1 (3.1) | 0 (0) | 0 (0) | 0 (0) | ||
|
| 57 (71.3) | 17 (53.1) | 40 (83.3) | 9 (56.3) | 31 (96.9) |
|
|
| iron deficiency anemia | 22 (27.5) | 9 (28.1) | 13 (27.1) | 2 (12.5) | 11 (34.4) | ||
| Diabetes mellitus | 21 (26.3) | 4 (12.5) | 17 (35.4) | 2 (12.5) | 15 (46.9) | ||
| Hypothyroidism | 15 (18.8) | 1 (3.1) | 14 (29.2) | 2 (12.5) | 12 (37.5) | ||
| Chronic infectionsa | 20 (25) | 6 (18.8) | 14 (29.2) | 2 (12.5) | 12 (37.5) | ||
| Malignancyb | 5 (6.3) | 1 (3.1) | 4 (8.3) | 3 (18.8) | 1 (3.1) | ||
| Hyperthyroidism | 2 (2.5) | 0 (0) | 2 (4.2) | 0 (0) | 2 (6.3) | ||
| Chronic kidney disease | 3 (3.8) | 0 (0) | 3 (6.3) | 0 (0) | 3 (9.4) | ||
| Cholestatic liver diseasec | 3 (3.8) | 1 (3.1) | 2 (4.2) | 1 (6.3) | 1 (3.1) | ||
| Sarcoidosis | 2 (2.5) | 1 (3.1) | 1 (2.1) | 0 (0) | 1 (3.1) | ||
| Sjogren syndrome | 2 (2.5) | 1 (3.1) | 1 (2.1) | 0 (0) | 1 (3.1) | ||
|
| 33 (41.3) | 13 (40.6) | 20 (41.7) | 6 (37.5) | 14 (43.8) |
|
|
| Depression | 30 (37.5) | 12 (37.5) | 18 (37.5) | 6 (37.5) | 12 (37.5) | ||
| Anxiety | 14 (17.5) | 4 (12.5) | 10 (20.8) | 1 (6.3) | 9 (28.1) | ||
| Stress | 10 (12.5) | 4 (12.5) | 6 (12.5) | 2 (12.5) | 4 (12.5) | ||
| Obsessive compulsive disorder | 3 (3.8) | 0 (0) | 3 (6.3) | 0 (0) | 3 (9.4) | ||
|
| 14 (17.5) | 3 (9.4) | 11 (22.9) | 1 (6.3) | 10 (31.3) |
|
|
| Peripheral neuropathy | 4 (5) | 1 (3.1) | 3 (6.3) | 0 (0) | 3 (9.4) | ||
| Migraine | 4 (5) | 2 (6.3) | 2 (4.2) | 1 (6.3) | 1 (3.1) | ||
| Lumbar hernia | 3 (3.8) | 0 (0) | 3 (6.3) | 0 (0) | 3 (9.4) | ||
| Cervical hernia | 1 (1.3) | 0 (0) | 1 (2.1) | 0 (0) | 1 (3.1) | ||
| Cerebrovascular accident | 1 (1.3) | 0 (0) | 1 (2.1) | 0 (0) | 1 (3.1) | ||
| Parkinson disease | 1 (1.3) | 0 (0) | 1 (2.1) | 0 (0) | 1 (3.1) | ||
| Alzheimer disease | 1 (1.3) | 0 (0) | 1 (2.1) | 0 (0) | 1 (3.1) | ||
- Chronic infectionsa: Helicobacter pylori-positive gastritis, in 12 (15%) patients; hepatitis B virus infection, odontogenic infection or chronic tonsillitis in each 3 (3.8%) patients; hepatic hydatid cyst, in 2 (2.5%) patients; toxocariasis, in 1 (1.3%) patient
- Malignancyb: Lymphoma, in 3 (3.8%) patients; lung carcinoma or endometrial carcinoma in 1 (1.3%) patient each
- Cholestatic liver diseasec: Liver cysts, primary biliary cirrhosis or sclerosing cholangitis in 1 (1.3%) patient each
Logistic regression model to evaluate the association of co-factors
| PN-associated co-factors | Xerosis Reference: nonxerosis group | Atopic Xerosis Reference: non-xerosis group | Non-atopic Xerosis Reference: non-xerosis group | Non-atopic Xerosis Reference: atopic xerosis group | ||||
|---|---|---|---|---|---|---|---|---|
| RR (95% CI) | RR (95% CI) | RR (95% CI) | RR (95% CI) | |||||
| Systemic cofactors | 4.04 (1.39 - 11.73) | 0.01 | 1.19 (0.35 - 4.06) | 0.79 | 25.08 (2.95 - 212.97) | 0.01 | 24.95 (2.27 - 274.4) | 0.01 |
| Dermatological co-factors | 1.08 (0.41 - 2.83) | 0.87 | 1.10 (0.33 - 3.73) | 0.88 | 1.25 (0.39 - 4.03) | 0.71 | 0.53 (0.11 - 2.45) | 0.41 |
| Psychological co-factors | 0.82 (0.69 - 0.82) | 0.69 | 0.86 (0.25 - 3.02) | 0.82 | 0.80 (.025 - 2.61) | 0.72 | 0.80 (0.19 - 3.47) | 0.77 |
| Neurological co-factors | 2.09 (0.50 - 8.69) | 0.31 | 0.65 (0.06 - 7.06) | 0.72 | 3.25 (0.68 - 15.55) | 0.14 | 3.61 (0.39 - 33.47) | 0.26 |
| Logistic regression model, Hosmer- Lemeshow test | P=0.82 | P=0.57 | P=0.92 | P=0.72 | ||||
PN, prurigo nodularis; RR, relative risk; %95 CI, 95% confidence interval
Figure 1Excoriated papulo nodular lesions on the exten sor surfaces of the lower ex tremities